Introduction:
Cellular Origins, a TTP company, has acquired the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge while CEO of SOTIO Biotech US. The ACTIA Platform is designed for autologous cell therapy manufacturing and allows for massively multiplex and distributed industrial automation. Cellular Origins plans to integrate the ACTIA Platform into its robotic solution for automated cell therapy manufacturing, called Constellation™. This acquisition aims to accelerate and expand research and development efforts to develop an efficient and scalable solution for large-scale production of cell therapies.
- Cellular Origins has acquired the ACTIA Platform IP for autologous cell therapy manufacturing.
- The ACTIA Platform offers massively multiplex and distributed industrial automation.
- Cellular Origins will integrate the ACTIA Platform into its robotic solution for cell therapy manufacturing, Constellation™.
- This acquisition aims to develop an efficient and scalable solution for large-scale production of cell therapies.
- The combination of the ACTIA Platform and Constellation™ will revolutionize cell therapy manufacturing and improve patient access to life-saving therapies.
Conclusion:
Cellular Origins’ acquisition of the ACTIA Platform IP marks a significant step in the development of an efficient and scalable solution for autologous cell therapy manufacturing. By integrating the ACTIA Platform into its robotic solution, Constellation™, Cellular Origins aims to revolutionize cell therapy manufacturing and improve patient access to life-saving therapies. This acquisition underscores Cellular Origins’ commitment to providing cost-effective and large-scale production of cell therapies that meet the needs of customers and ensure long-term success.
